是否存在从轻度认知障碍（MCI）向认知正常的逆转？对阿尔茨海默病生物标志物谱的分析。
Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles.
机构信息
Department of Neurology,Korea University Medical College and Korea University Ansan Hospital,South Korea.
Department of Psychiatry,Korea University Medical College and Korea University Ansan Hospital,South Korea.
出版信息
Int Psychogeriatr. 2015 Mar;27(3):429-37. doi: 10.1017/S1041610214002129. Epub 2014 Sep 26.
BACKGROUND
We investigated the characteristics of Alzheimer's disease (AD) biomarkers for mild cognitive impairment (MCI) reversion to cognitively normal (CN).
METHODS
Of a total of 1,233 participants from the ADNI database, 42 participants with MCI reversion to CN (MCIr), 778 with MCI, and 413 CN were obtained. We evaluated demographics, clinical outcomes, medication use, MCI type, and AD biomarkers, including genetic, cerebrospinal fluid, imaging, and neuropsychological data.
RESULTS
This study showed that the differences between MCIr and CN were only age, Mini-Mental State Examination, and Clinical Dementia Rating - Sum of Boxes, but the differences between MCIr and MCI were not only clinical outcomes but also AD biomarkers, including genetic, cerebrospinal fluid, imaging, and neuropsychological data. Overall, MCIr may be similar to CN and not MCI in clinical characteristics.
CONCLUSIONS
With assessment of MCI reversion to CN, the possibility of false-positive errors should be considered. With the assistance of AD biomarkers, MCI can be evaluated more accurately than the conventional criteria.
背景
我们研究了阿尔茨海默病（AD）生物标志物在轻度认知障碍（MCI）向认知正常（CN）逆转的特征。
方法
从 ADNI 数据库中总共纳入了 1233 名参与者，其中 42 名 MCI 向 CN 逆转（MCIr）、778 名 MCI 和 413 名 CN。我们评估了人口统计学、临床结局、药物使用、MCI 类型和 AD 生物标志物，包括遗传、脑脊液、影像学和神经心理学数据。
结果
本研究表明，MCIr 与 CN 之间的差异仅为年龄、简易精神状态检查和临床痴呆评定量表-总评分，而 MCIr 与 MCI 之间的差异不仅是临床结局，还包括 AD 生物标志物，包括遗传、脑脊液、影像学和神经心理学数据。总体而言，MCIr 在临床特征上可能与 CN 而非 MCI 相似。
结论
评估 MCI 向 CN 的逆转时，应考虑假阳性错误的可能性。借助 AD 生物标志物，可以比传统标准更准确地评估 MCI。
Zotero 插件